BMT Tandem Meetings, Combined Annual Meetings of the Center for International Blood & Marrow Transplant Research (CIBMTR) and the American Society for Blood and Marrow Transplantation (ASBMT)
Atara's collaborating investigators will present an oral encore presentation of the interim results for tabelecleucel (formerly known as ATA129) from a multicenter expanded access protocol (EAP) study for patients with EBV associated cancers. These results were previously presented at the 59th American Society of Hematology (ASH) Annual Meeting on December 11, 2017. The BMT Tandem Meeting will be held February 21-25, 2017, at the Salt Palace Convention Center in Salt Lake City, UT. Details for the presentation are as follows:
Abstract Title: Efficacy and Safety of ATA129, Partially Matched Allogeneic Third-Party Epstein-Barr Virus-Targeted Cytotoxic T Lymphocytes in a Multicenter Study for Post-Transplant Lymphoproliferative Disorder
Lead Author: Susan E. Prockop, M.D.
Session Title: Oral Abstracts - Session B: Allogeneic